Eminent journalist Dileep Padgaonkar who headed the group of three Central interlocutors for Jammu and Kashmir said on Thursday that the thrust of their report was to empower the people of Jammu and Kashmir so that they were able to exercise their civil and political rights in full measure. The 176-page report of the group of Central interlocutors was uploaded on the website of Union Home Ministry on Thursday, seven months...

By not resolving the definition of ‘public purpose,' the Land Acquisition Bill keeps the door open for misuse It has taken more than 110 years for the government to draft a new Land Acquisition, Rehabilitation and Resettlement Bill. But despite mounting evidence of widespread misuse of government authority in taking over farm land and the increasing protests against the legal ambiguity that abets such exploitative practices, the revised legislation remains dubiously...

In a Bangladeshi folk story, a disabled grandfather is carried by his son in a basket, to be abandoned in the forest. On seeing this, the grandson calls out, 'Father, please be sure to bring back the basket. I will need it when you grow old'. Three thousand ageing men and women gathered in Delhi in the blazing midsummer heat to demand a universal pension for all aged people, not...

Union Agriculture Minister Sharad Pawar’s statement in Parliament that the Government plans to shift subsidies from chemical fertilizers to organic manures has finally earned him some admiration from grassroots organisations working with small and marginal farmers in the country’s vast dry-lands. Pawar’s statement, if translated into policy action, may go a long way in improving the condition of some of India’s poorest farmers in the rain-fed areas which account for...

German drugmaker Bayer AG has demanded the withdrawal of the country's first compulsory licence given to Natco Pharma, arguing that a three-fourth reduction in the price of the anti-cancer drug by another Indian firm has made the permit redundant and its patent itself is vulnerable to being revoked. In March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original...